Supplementary data

Extended Version of Materials and Methods

Study Design and Patients

This was an open-label, single-center, randomized study (Registered at Australian New Zealand Clinical Trials Registry: ACTRN1260000016033ANZCTR). Patients were recruited from a transplant center at the Charles University Teaching Hospital, Pilsen, Czech Republic. From November 2007 through April 2012, eligible for inclusion were all adult renal transplant recipients with recipient (R) and/or donor (D) positive CMV serology. Exclusion criteria included D-/R- serostatus, allergy to (val)ganciclovir or (val)acyclovir, severe leukopenia or thrombocytopenia, participation in another clinical trial and inability to provide informed consent. The study was approved by the local ethics committee and conducted in compliance with the Declaration of Helsinki. The clinical and research activities being reported are consistent with the Principles of the Declaration of Istanbul as outlined in the 'Declaration of Istanbul on Organ Trafficking and Transplant Tourism'. Written informed consent was obtained before enrollment. Patients were randomized by the transplant physician using a random-number table, at a 1:1 ratio with the use of block sizes of 4, to valganciclovir or valacyclovir prophylaxis. The order of interventions varied randomly within each block. Randomization was stratified by D/R CMV serostatus. Sequentially numbered sealed envelopes were used for allocation concealment.

Interventions

Patients received valganciclovir (Valcyte, Hoffman-La Roche, Grenzach-Wyhlen, Germany) at a dose of 900mg daily or valacyclovir (Valtrex, Glaxo Wellcome, Dartford, UK) at a dose of 2g four times daily for 3 months beginning day 7 post-transplant at the latest. Antiviral drugs doses were tapered based on renal function according to manufacturers' instructions. PCR for CMV DNA from whole blood was performed at 2-week intervals for the first 3 months and at 4, 5, 6, 9, and 12 months thereafter. PCR was likewise performed if clinically required. Asymptomatic CMV DNAemia occurring during or after prophylaxis was not treated regardless of the viral load. Patients developing severe CMV disease were treated initially by intravenous ganciclovir (Cymevene, Hoffman-La Roche, Basel, Switzerland) at a dose of 5 mg/kg every 12 hours. Other patients were given valganciclovir (900 mg twice daily). Duration of therapy was 21 days or longer in cases with persistent CMV viremia.

The standard immunosuppressive protocol included cyclosporine, mycophenolate mofetil and corticosteroids. Immunological high-risk patients received induction by antithymocyte globulin (Thymoglobuline, Genzyme, Marcy I'Eoile, France) and tacrolimus. Recipients of grafts from highly marginal donors (donation after cardiac death, \geq 70 years old, donors with hypertension and significant nephrosclerosis on biopsy, and/or dual kidney transplantation) were treated with anti-IL2R monoclonal antibody (basiliximab) and low-dose tacrolimus. Patients received prophylaxis with trimethoprim-sulfamethoxazole for 4 months and oral amphotericin solution for 1 month. Plasma was tested for polyoma virus DNAemia every month for the first 6 months and at 9 and 12 months with preemptive immunosuppression reduction at a significant viral load (\geq 10,000 copies/mL).

Study Outcomes and Follow-up

The primary end points were the incidences of CMV DNAemia and biopsy-proven acute rejection (BPAR) at 12 months post-transplant. Secondary end points included CMV disease, patient and graft survival (not censored for death), subclinical rejection and IF/TA assessed by protocol biopsy at month 3, renal function, other infections, and safety evaluated by recording adverse events and routine laboratory parameters. In addition, other potential indirect effects of CMV such as cardiovascular events or new-onset diabetes mellitus, malignancy, and economic data were recorded prospectively. All patients remained on follow-up for a minimum of 12 months post-transplant or until death.

CMV DNAemia was defined by detection of CMV DNA. CMV disease was defined as symptomatic CMV viremia and embraced both CMV syndrome and tissue-invasive disease (1). Suspected acute rejection was confirmed by core biopsy using the up-dated Banff classification (2). BPAR was defined as grade \geq IA or antibody-mediated rejection.

Quantitative PCR for CMV DNA

Quantitative real-time PCR was performed using a commercially available kit (RealStar® CMV PCR kit 1.0, Altona Diagnostics, Germany) according to manufacturers' instructions on a Rotor-GeneTM 2000/3000 system (Corbett Research, Australia). DNA was isolated from 200 μ L of whole blood using a commercially available kit

(QuickGene DNA whole blood kit S (DB-S), Kurabo, Japan). Sensitivity of the investigation was 50 copies/mL of whole blood. Physicians assessing the PCR results were blinded to the study group of patients.

Quantitative PCR for Polyomavirus DNA

Quantification of BK virus (BKV) was performed using commercial diagnostic kit (BK Virus R-geneTM-Quantification kit, Argene/Biomérieux, Verniolle, France) according to manufacturer's protocol. Amplification reaction targets small T Antigen and detects BKV with sensitivity of 65 copies/mL. PCR was run on Rotor Gene Q (Qiagen, Gaithersburg, USA). DNA was isolated from 200 µL of plasma by QIAamp DNA Blood Mini kit (Qiagen, Gaithersburg, USA). The efficiency of DNA extraction and PCR inhibition was checked in each sample using Real Time PCR amplification of control artificial DNA. Physicians assessing the PCR results were blinded to the study group of patients.

Biopsy Sample Processing

Indications for biopsy included an increase in serum creatinine by more than 20% that could not be explained otherwise, and delayed graft function. Biopsy was also undertaken in cases of suboptimal development of graft function (serum creatinine >160 µmol/L). In patients with functioning grafts, protocol biopsy was performed at 3 months. Using a 16- or 18-gauge needle (biopsy gun) a minimum of two cores were obtained. Tissues for light microscopy were fixed in 4% formaldehyde, embedded in paraffin using routine procedure. Sections 3µm thick were cut from tissue blocks and stained with hematoxylin and eosin, blue trichrome, silver staining, and Congo red staining. Immunohistochemical analysis was performed in the Ventana automated slide stainer without manual antigen retrieval and was detected using Ventana ultraView universal DAB detection kit (Ventana-Roche, Tucson, AZ) as recommended by manufacturer. The primary antibodies against C4d (Venatana-Roche) and SV40 (Ventana-Roche), p53 (Ventana-Roche), and CMV (Dako, Glostrup, Denmark) were used. Appropriate positive controls were employed. In all biopsies, fresh tissue samples were examined using immunoflorescence staining for C4d (Biomedica Grouppe, Vienna, Austria) and for C3 (Dako) depositions in peritubular capillaries paralelly. All biopsies were evaluated according to the the up-dated Banff classification (2). Pathologists evaluating biopsy samples were blinded to the study group of the patients.

Sample Size and Statistical Analysis

The anticipated CMV DNAemia and BPAR rates in the valacyclovir group were 60% and 12%, respectively (3, 4). To detect a reduction in the incidence of CMV DNAemia to 35% and an increase in the incidence of BPAR to 30% in the valganciclovir group it was necessary to enroll at least 60 and 72 patients to ensure 80% power for detection of a treatment difference with type 1 error of 0.05. Given the anticipated number of patients to be lost to follow-up, a total of 80 patients were planned to enroll. Because of a clinically important trend toward a lower BPAR rate in the valganciclovir group (12.5% vs. 25%; P=0.14 by not adjusted log-rank test) after analysis of a planned study population, it was decided to increase sample size. With the assumption of the same difference in BPAR, at least 114 patients were required. Finally, 124 patients were planned to enroll anticipating patients to be lost to follow-up.

Quantitative parametric data were compared using Student's t-test and the Mann-Whitney U-test in nonparametric distribution. Qualitative data were analyzed using χ^2 with Yates correction or Fisher's exact test. Incidence of CMV DNAemia and disease, BPAR, patient and graft survival, polyoma BKV viremia and polyomavirus-associated nephropathy were calculated using Kaplan-Meier curves, with the log-rank test used for comparison. The Cox proportional hazard model adjusting for age, previous transplantation, peak panel reactive antibodies, HLA mismatches, calcineurin inhibitor, induction therapy, donor age, donor type, expanded criteria donor, and delayed graft function was used to calculate aHR and 95% CI for selected variables. Data were analyzed according to the intention-to-treat principle. Statistical calculations were made using SigmaStat 3.1 and Statistica 9.0 software. Values of P<0.05 were considered statistically significant.

References

- Humar A, Michaels M, Monitoring AIWGoID: American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. *Am J Transplant*, 6: 262-274, 2006
- 2. Sis B, Mengel M, Haas M, Colvin RB, Halloran PF, Racusen LC, Solez K, Baldwin WM, 3rd, Bracamonte ER, Broecker V, Cosio F, Demetris AJ, Drachenberg C, Einecke G, Gloor J, Glotz D, Kraus E, Legendre C, Liapis H, Mannon RB, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Rodriguez ER, Seron D, Seshan S, Suthanthiran M, Wasowska BA, Zachary A, Zeevi

A: Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. *Am J Transplant*, 10: 464-471, 2010

- Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V: Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. *Am J Transplant*, 8: 69-77, 2008
- Reischig T, Jindra P, Mares J, Cechura M, Svecova M, Hes O, Opatrny K, Jr., Treska V: Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. *Transplantation*, 79: 317-324, 2005

Supplementary Table 1. Immunosuppressive therapy during the study

(n = 60) $(n = 50)$ Switch to taroniums during 1" year"16 (64)24 (69)0.93Switch to cyclosporine during 1" year"4 (11)1 (4)0.39Bardy (<3) months) mycophenolate mofetil withdrawal"15 (25)16 (27)0.96Maintenance immunosuppression"47 (78)41 (71)0.46Cyclosporine13 (22)17 (29)0.49Mycophenolate mofetil59 (98)57 (98)0.49Prednisone60 (100)57 (98)0.49Month 3714 (24)16 (29)Tacrolimus45 (76)40 (71)0.71Cyclosporine14 (24)16 (29)Mycophenolate mofetil56 (95)52 (93)0.94Prednisone59 (100)55 (98)0.98Month 12"743 (80)0.94Cyclosporine13 (23)11 (20)Mycophenolate mofetil55 (96)51 (94)0.95Mycophenolate mofetil55 (96)51 (94)0.95Mycophenolate mofetil241 ± 53233 ± 530.56Month 12"121 ± 47145 ± 000.44Cyclosporine13 (23)11 (20)94Prednisone55 (96)51 (94)0.95Mycophenolate mofetil84 (57)194 ± 430.56Month 1194 ± 53233 ± 530.56Month 3194 ± 53134 ± 520.45Month 13117 ± 21118 ± 490.87Tacrolimus117 ± 21118 ± 490.87Tacrol	Variables	Valganciclovir	Valacyclovir	P value
Switch to carcolinus during 1 ^a year ^a 16 (64)24 (69)0.93Switch to cyclosporine during 1 ^a year ^b 4 (11)1 (4)0.39Early (<3 months) mycophenolate mofetil withdrawal ^c 15 (25)16 (27)0.96Maintenance immunosuppression ^d 4 (78)41 (71)0.46Cyclosporine13 (22)17 (29)0.99Mycophenolate mofetil59 (98)57 (98)0.49Prednisone60 (100)57 (98)0.99Month 3777Tacrolinus44 (77)40 (71)0.71Cyclosporine14 (24)16 (29)7Mycophenolate mofetil59 (100)55 (98)0.98Month 12'743 (80)0.94Tacrolinus44 (77)43 (80)0.94Cyclosporine trough level (ng/mL; mean \pm SD) ^d 711 (20)Week 1241 \pm 53233 \pm 530.56Month 1250 \pm 94249 \pm 760.96Month 1250 \pm 94249 \pm 760.96Month 1250 \pm 94249 \pm 760.96Month 1108 \pm 56213 \pm 500.24Month 1119 \pm 56213 \pm 500.24Month 1119 \pm 56213 \pm 500.24Month 1126 \pm 500.2449 \pm 760.96Month 1121 \pm 47145 \pm 600.24Month 1128 \pm 500.2449 \pm 760.96Month 1119 \pm 53118 \pm 470.70Month		(n = 60)	(n = 59)	
Switch to cyclosporine during 1 th yearb4 (11)1 (4)0.39Early (<3 months) mycophenolate mofetil withdrawal*	Switch to tacrolimus during 1 st year ^a	16 (64)	24 (69)	0.93
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Switch to cyclosporine during 1 st year ^b	4 (11)	1 (4)	0.39
Maintenance immunosuppression ^d Month 1Tacrolimus47 (78)41 (71)0.46Cyclosporine13 (22)17 (29)Mycophenolate mofetil59 (98)57 (98)0.49Predinisone60 (100)57 (98)0.99Month 3TT7Tacrolimus45 (76)40 (71)0.71Cyclosporine14 (24)16 (29)0.98Month 256 (95)52 (93)0.94Prednisone59 (90)55 (98)0.98Month 12'TTTTacrolimus44 (77)43 (80)0.94Cyclosporine13 (23)11 (20)11 (20)Mycophenolate mofetil54 (95)50 (93)0.94Prednisone55 (96)51 (94)0.95Cyclosporine trough level (ng/mL; mean \pm SD) ^d TTWeek 1241 \pm 53233 \pm 530.56Month 1250 \pm 94249 \pm 760.96Month 3198 \pm 56213 \pm 520.45Month 6121 \pm 47145 \pm 600.24Month 1119 \pm 6.311.84 \pm 70.70Month 1119 \pm 6.311.84 \pm 70.70Month 111.92 \pm 6.311.84 \pm 70.70Month 111.92 \pm 6.311.84 \pm 70.70Month 111.92 \pm 6.31.94 \pm 6.51Month 111.92 \pm 0.251.90 \pm 0.25Month 11.69 \pm 0.451.73 \pm 0.49Month 11.69 \pm 0.451.73 \pm 0.49Mo	Early (< 3 months) mycophenolate mofetil withdrawal ^c	15 (25)	16 (27)	0.96
Month 1 Tacrolimus 41 (71) 0.46 Cyclosporine 13 (22) 17 (29) Mycophenolate mofetil 59 (98) 57 (98) 0.49 Prednisone 60 (0 (00) 57 (98) 0.49 Month 3 Tacrolimus 45 (76) 40 (71) 0.71 Cyclosporine 14 (24) 16 (29) Mycophenolate mofetil 56 (95) 52 (93) 0.94 Prednisone 59 (100) 55 (98) 0.98 Month 12' Tacrolimus 44 (77) 43 (80) 0.94 Cyclosporine 13 (23) 11 (20) Mycophenolate mofetil 54 (95) 50 (93) 0.94 Prednisone 52 (96) 51 (94) 0.95 Cyclosporine trough level (ng/mL; mean \pm SD) ^d 0.45 Month 1 233 \pm 55 0.13 \pm 52 0.45 Month 3 198 \pm 56 213 \pm 52 0.45	Maintenance immunosuppression ^d			
Tarcolimus 41 (71) 0.46 Cyclosporine 13 (22) 17 (29) Mycophenolate mofetil 59 (98) 57 (98) 0.49 Prednisone 60 (100) 57 (98) 0.99 Month 3 Tarcolimus 45 (76) 40 (71) 0.71 Tarcolimus 45 (76) 40 (71) 0.71 0.94 Cyclosporine 14 (24) 16 (29) 0.94 Mycophenolate mofetil 56 (95) 52 (93) 0.94 Prednisone 59 (100) 55 (98) 0.98 Month 12' Tarcolimus 44 (77) 43 (80) 0.94 Mycophenolate mofetil 54 (95) 50 (93) 0.94 Prednisone 55 (96) 51 (94) 0.95 Cyclosporine 13 (23) 11 (20) 10 Mycophenolate mofetil 23 ± 53 0.56 0.95 Cyclosporine 13 (23) 11 (20) 0.94 Mycophenolate mofetil 23 ± 53 0.56 0.94 Month 1 241 ± 53 233 ± 53 0.56 Month 5 117 ± 21 <td< td=""><td>Month 1</td><td></td><td></td><td></td></td<>	Month 1			
$\begin{array}{cccc} Cyclosporine & 13 (22) & 17 (29) \\ \mbox{Mycophenolate mofetil} & 59 (98) & 57 (98) & 0.49 \\ \mbox{Prednisone} & 60 (100) & 57 (98) & 0.99 \\ \mbox{Month 3} & & & & & & & & & & & & & & & & & & $	Tacrolimus	47 (78)	41 (71)	0.46
Mycophenolate mofetil59 (98)57 (98)0.49Prednisone60 (100)57 (98)0.99Month 3Tacrolinus45 (76)40 (71)0.71Tacrolinus45 (76)40 (71)0.71Cyclosporine14 (24)16 (29)Mycophenolate mofetil56 (95)52 (93)0.94Prednisone59 (100)55 (98)0.98Month 12'TTTTacrolinus44 (77)43 (80)0.94Cyclosporine13 (23)11 (20)TMycophenolate mofetil54 (95)50 (93)0.94Prednisone55 (96)51 (94)0.95Cyclosporine trough level (ng/mL; mean \pm SD) ^d TTTWeek 1250 ±94249 \pm 760.96Month 3198 \pm 56213 \pm 520.45Month 6121 \pm 47145 \pm 600.24Month 1198 \pm 56213 \pm 520.45Month 12117 \pm 21118 \pm 490.87Tacrolinus trough level (ng/mL; mean \pm SD) ^d TTTWeek 110.6 \pm 4.610.5 \pm 6.60.99Month 111.9 \pm 6.311.8 \pm 4.70.70Month 11.92 \pm 0.251.90 \pm 0.220.63Month 11.92 \pm 0.251.90 \pm 0.220.63Month 11.69 \pm 0.451.73 \pm 0.490.56Month 11.69 \pm 0.451.73 \pm 0.490.56Month 11.69 \pm 0.451.73 \pm 0.490.56	Cyclosporine	13 (22)	17 (29)	
Prednisone $60 (100)$ $57 (98)$ 0.99 Month 3 7 7 7 98 0.99 Month 3 1 45 (76) 40 (71) 0.71 Cyclosporine 14 (24) 16 (29) 0.94 Mycophenolate mofetil 56 (95) 52 (93) 0.94 Prednisone 59 (100) 55 (98) 0.98 Month 12' 7 7 43 (80) 0.94 Cyclosporine 13 (23) 11 (20) 7 Mycophenolate mofetil 54 (95) 50 (93) 0.94 Prednisone 55 (96) 51 (94) 0.95 Cyclosporine trough level (ng/mL; mean \pm SD) ^d Week 1 233 \pm 53 0.56 Month 1 250 \pm 94 249 \pm 76 0.96 Month 1 198 \pm 56 213 \pm 52 0.45 Month 6 121 \pm 47 145 \pm 60 0.24 Month 1 198 \pm 6.3 11.8 \pm 4.7 0.70 Month 1 11.9 \pm 6.3 11.8 \pm 4.7 0.70	Mycophenolate mofetil	59 (98)	57 (98)	0.49
Month 3 Tacrolimus 45 (76) 40 (71) 0.71 Tacrolimus 44 (24) 16 (29) 0.94 Prednisone 59 (100) 55 (98) 0.98 Month 12° 1 1 0.94 Tacrolimus 59 (100) 55 (98) 0.98 Month 12° 1 1 0.94 Cyclosporine 13 (23) 11 (20) 0.94 Mycophenolate mofetil 54 (95) 50 (93) 0.94 Prednisone 25 (96) 51 (94) 0.95 Cyclosporine trough level (ng/mL; mean \pm SD) ^d 1 120 0.96 Week 1 241 \pm 53 233 \pm 53 0.56 Month 1 198 \pm 56 213 \pm 52 0.45 Month 6 121 \pm 47 145 \pm 60 0.24 Month 12 117 \pm 21 118 \pm 49 0.87 Tacrolimus trough level (ng/mL; mean \pm SD) ^d 10.6 \pm 4.6 10.5 \pm 6.6 0.99 Month 12 119 \pm 6.3 11.8 \pm 4.7 0.70 Month 12	Prednisone	60 (100)	57 (98)	0.99
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Month 3			
Cyclosporine14 (24)16 (29)Mycophenolate mofetil56 (95)52 (93)0.94Prednisone59 (100)55 (98)0.98Month 12°Tacrolimus44 (77)43 (80)0.94Cyclosporine13 (23)11 (20)Mycophenolate mofetil54 (95)50 (93)0.94Prednisone55 (96)51 (94)0.95Cyclosporine trough level (ng/mL; mean \pm SD) ^d 249 ± 76 0.96Week 1250 ± 94 249 ± 76 0.96Month 1250 ± 94 249 ± 76 0.96Month 3198 ± 56 213 ± 52 0.45Month 6121 ± 47 145 ± 60 0.24Month 12117 ± 21 118 ± 49 0.87Tacrolimus trough level (ng/mL; mean \pm SD) ^d $Wek 1$ 10.6 ± 4.6 10.5 ± 6.6 0.99Month 111.9 ± 6.3 11.8 ± 4.7 0.70Month 39.1 ± 3.3 6.5 ± 2.0 0.64Month 110.6 ± 4.6 10.5 ± 6.6 0.99Month 111.9 ± 6.3 11.8 ± 4.7 0.70Month 39.1 ± 3.4 9.1 ± 3.6 1.0Month 66.5 ± 2.0 6.5 ± 2.2 0.13Month 1210.6 ± 4.61 10.5 ± 6.61 0.94Month 66.3 ± 2.3 6.5 ± 2.1 0.64Month 61.69 ± 0.45 1.73 ± 0.49 0.56Month 121.92 ± 0.25 1.90 ± 0.22 0.63Month 61.34 ± 0.55 1.39 ± 0.58 0.49Mon	Tacrolimus	45 (76)	40 (71)	0.71
Mycophenolate mofetil56 (95)52 (93)0.94Prednisone59 (100)55 (98)0.98Month 12°Tacrolimus44 (77)43 (80)0.94Cyclosporine13 (23)11 (20)10 (20)Mycophenolate mofetil54 (95)50 (93)0.94Prednisone55 (96)51 (94)0.95Cyclosporine trough level (ng/mL; mean \pm SD) ^d 241 \pm 53233 \pm 530.56Month 1250 \pm 94249 \pm 760.96Month 2121 \pm 47145 \pm 600.24Month 6121 \pm 47145 \pm 600.24Month 6117 \pm 21118 \pm 490.87Tacrolimus trough level (ng/mL; mean \pm SD) ^d Wext10.6 \pm 4.610.5 \pm 6.60.99Month 611.9 \pm 6.311.8 \pm 4.70.70Month 111.9 \pm 6.311.8 \pm 4.70.70Month 119.9 \pm 6.311.8 \pm 4.70.70Month 119.2 \pm 0.251.90 \pm 0.220.63Month 11.92 \pm 0.251.90 \pm 0.220.63Month 11.69 \pm 0.451.73 \pm 0.490.56Month 31.45 \pm	Cyclosporine	14 (24)	16 (29)	
Predmisone 59 (100) 55 (98) 0.98 Month 12" Tacrolimus 44 (77) 43 (80) 0.94 Tacrolimus 44 (77) 43 (80) 0.94 Cyclosporine 13 (23) 11 (20) Mycophenolate mofetil 54 (95) 50 (93) 0.94 Prednisone 55 (96) 51 (94) 0.95 Cyclosporine trough level (ng/mL; mean \pm SD) ^d Week 1 241 \pm 53 233 \pm 53 0.56 Month 3 198 \pm 56 213 \pm 52 0.45 Month 6 121 \pm 47 145 \pm 60 0.24 Month 12 117 \pm 21 118 \pm 49 0.87 Tacrolimus trough level (ng/mL; mean \pm SD) ^d Week 1 10.6 \pm 4.6 10.5 \pm 6.6 0.99 Month 1 11.9 \pm 6.3 11.8 \pm 4.7 0.70 Month 3 9.1 \pm 3.4 9.1 \pm 3.6 1.0 Month 6 6.5 \pm 2.0 6.5 \pm 2.2 0.13 Mycophenolate mofetil dos	Mycophenolate mofetil	56 (95)	52 (93)	0.94
Month 12° 44 (7) 43 (80) 0.94 Tarcolimus 44 (7) 43 (80) 0.94 Tarcolimus 53 (23) 11 (20) Mycophenolate mofetil 54 (95) 50 (93) 0.94 Prednisone 55 (96) 51 (94) 0.95 Cyclosporine trough level (ng/mL; mean \pm SD) ^d Week 1 241 \pm 53 233 \pm 53 0.56 Month 3 198 \pm 56 213 \pm 52 0.45 Month 6 121 \pm 47 145 \pm 60 0.24 Month 6 121 \pm 47 145 \pm 60 0.24 Month 12 117 \pm 21 118 \pm 49 0.87 Tacrolimus trough level (ng/mL; mean \pm SD) ^d Week 1 10.6 \pm 4.6 10.5 \pm 6.6 0.99 Month 1 1.9 \pm 6.3 11.8 \pm 4.7 0.70 Month 3 9.1 \pm 3.4 9.1 \pm 3.6 1.0 Month 6 6.5 \pm 2.0 6.5 \pm 2.2 0.13 Month 1 1.92 \pm 0.25 1.90 \pm 0.22 0.63 Month 1 1.69 \pm 0.45 1.73 \pm 0.49 0.56 Month 1 1.69 \pm 0.55 1.39 \pm 0.	Prednisone	59 (100)	55 (98)	0.98
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Month 12 ^e			
Cyclosporine13 (23)11 (20)Mycophenolate mofetil54 (95)50 (93)0.94Prednisone55 (96)51 (94)0.95Cyclosporine trough level (ng/mL; mean \pm SD) ^d Week 1241 \pm 53233 \pm 530.56Month 1198 \pm 56213 \pm 520.45Month 6121 \pm 47145 \pm 600.24Month 12118 \pm 490.87Tacrolimus trough level (ng/mL; mean \pm SD) ^d Week 110.6 \pm 4.610.5 \pm 6.60.99Month 1211.8 \pm 4.70.70Month 39.1 \pm 3.49.1 \pm 3.61.0Month 410.9 \pm 6.311.8 \pm 4.70.70Month 56.5 \pm 2.06.5 \pm 2.20.13Month 66.5 \pm 2.06.5 \pm 2.20.13Month 126.3 \pm 2.36.5 \pm 2.10.64Mycophenolate mofetil dose (g per day; mean \pm SD) ^d Initial1.99 \pm 0.251.90 \pm 0.220.63Month 11.69 \pm 0.451.73 \pm 0.490.56Month 11.45 \pm 0.491.53 \pm 0.570.49Month 11.34 \pm 0.551.39 \pm 0.580.49Month 121.24 \pm 0.251.39 \pm 0.580.49Month 121.34 \pm 0.551.39 \pm 0.580.49Month 121.34 \pm 0.551.39 \pm 0.580.51Mycophenolic acid AUC (mg*h/L; mean \pm SD) ^d Week 120 \pm 0.20 \pm 0.20 \pm 3.0570.49<	Tacrolimus	44 (77)	43 (80)	0.94
Mycophenolate mofetil54 (95)50 (93)0.94Prednisone55 (96)51 (94)0.95Cyclosporine trough level (ng/mL; mean \pm SD) ^d uuuWeek 1241 \pm 53233 \pm 530.56Month 1250 \pm 94249 \pm 760.96Month 3198 \pm 56213 \pm 520.45Month 6121 \pm 47145 \pm 600.24Month 12117 \pm 21118 \pm 490.87Tacrolimus trough level (ng/mL; mean \pm SD) ^d uuuWeek 110.6 \pm 4.610.5 \pm 6.60.99Month 111.9 \pm 6.311.8 \pm 4.70.70Month 39.1 \pm 3.49.1 \pm 3.61.0Month 66.5 \pm 2.06.5 \pm 2.20.13Month 66.3 \pm 2.36.5 \pm 2.10.64Mycophenolate mofetil dose (g per day; mean \pm SD) ^d uuInitial1.92 \pm 0.251.90 \pm 0.220.63Month 11.45 \pm 0.491.53 \pm 0.570.49Month 11.25 \pm 0.561.39 \pm 0.580.49Month 121.25 \pm 0.561.39 \pm 0.580.51Mycophenolic acid AUC (mg*h/L; mean \pm SD)uuuPrednisone dose (mg per day; mean \pm SD) ^d uuuWeek 120 \pm 20 \pm 0.51Month 310 \pm 10 \pm 0.45Month 310 \pm 10 \pm 0.65Month 1110 \pm 0.650.61Month 310 \pm 1.3	Cyclosporine	13 (23)	11 (20)	
Predinisone55 (96)51 (94)0.95Cyclosporine trough level (ng/mL; mean \pm SD) ^d 241 \pm 53233 \pm 530.56Week 1250 \pm 94249 \pm 760.96Month 1198 \pm 56213 \pm 520.45Month 6121 \pm 47145 \pm 600.24Month 12117 \pm 21118 \pm 490.87Tacrolimus trough level (ng/mL; mean \pm SD) ^d $\mathbf{10.6 \pm 4.6}$ 10.5 \pm 6.60.99Wonth 111.9 \pm 6.311.8 \pm 4.70.70Month 39.1 \pm 3.49.1 \pm 3.61.0Month 66.5 \pm 2.06.5 \pm 2.20.13Month 126.3 \pm 2.36.5 \pm 2.10.64Mycophenolate mofetil dose (g per day; mean \pm SD) ^d $\mathbf{1.92 \pm 0.25}$ 1.90 \pm 0.220.63Month 11.69 \pm 0.451.73 \pm 0.490.56Month 31.45 \pm 0.491.53 \pm 0.570.49Month 61.34 \pm 0.551.39 \pm 0.580.51Mycophenolic acid AUC (mg*h/L; mean \pm SD) $\mathbf{1.25 \pm 0.56}$ 1.34 \pm 0.580.51Mycophenolic acid AUC (mg*h/L; mean \pm SD) $\mathbf{20 \pm 0}$ $\mathbf{20 \pm 0}$ $\mathbf{20 \pm 3}$ 0.75Month 113 \pm 213 \pm 30.60Month 110 \pm 110 \pm 20.85Month 113 \pm 213 \pm 30.60Month 310 \pm 1 <t< td=""><td>Myconhenolate mofetil</td><td>54 (95)</td><td>50 (93)</td><td>0.94</td></t<>	Myconhenolate mofetil	54 (95)	50 (93)	0.94
Cyclosporine trough level (ng/mL; mean \pm SD) ^d 241 \pm 53 233 \pm 53 0.56 Week 1 250 \pm 94 249 \pm 76 0.96 Month 1 250 \pm 94 249 \pm 76 0.96 Month 3 198 \pm 56 213 \pm 52 0.45 Month 6 121 \pm 47 145 \pm 60 0.24 Month 12 117 \pm 21 118 \pm 49 0.87 Tacrolinus trough level (ng/mL; mean \pm SD) ^d Week 1 10.6 \pm 4.6 10.5 \pm 6.6 0.99 Month 1 11.9 \pm 6.3 11.8 \pm 4.7 0.70 Month 3 9.1 \pm 3.4 9.1 \pm 3.6 1.0 Month 6 6.5 \pm 2.0 6.5 \pm 2.2 0.13 Month 12 6.3 \pm 2.3 6.5 \pm 2.1 0.64 Mycophenolate mofetil dose (g per day; mean \pm SD) ^d Initia 1.92 \pm 0.25 1.90 \pm 0.22 0.63 Month 1 1.69 \pm 0.45 1.73 \pm 0.49 0.56 Month Moth 12 1.25 \pm 0.56 1.34 \pm 0.58 0.51 Mycophenolic acid AUC (mg*h/L; mean \pm SD) 44 \pm 18 39 \pm 26 0.11 Month 3 47 \pm 24	Prednisone	55 (96)	51 (94)	0.95
Week 1 241 ± 53 233 ± 53 0.56 Month 1 250 ± 94 249 ± 76 0.96 Month 3 198 ± 56 213 ± 52 0.45 Month 6 121 ± 47 145 ± 60 0.24 Month 12 117 ± 21 118 ± 49 0.87 Tacrolimus trough level (ng/mL; mean \pm SD) ^d 117 ± 21 118 ± 47 0.70 Week 1 0.6 ± 4.6 10.5 ± 6.6 0.99 Month 3 9.1 ± 3.4 9.1 ± 3.6 1.0 Month 6 6.5 ± 2.0 6.5 ± 2.2 0.13 Month 6 6.3 ± 2.3 6.5 ± 2.1 0.64 Mycophenolate mofetil dose (g per day; mean \pm SD) ^d 1192 ± 0.25 1.90 ± 0.22 0.63 Month 1 1.69 ± 0.45 1.73 ± 0.49 0.56 Month 6 1.34 ± 0.55 1.39 ± 0.58 0.49 Month 6 1.34 ± 0.55 1.39 ± 0.58 0.49 Month 6 1.34 ± 0.55 1.39 ± 0.58 0.49 Month 7 1.25 ± 0.56 1.34 ± 0.58 0.51 Mycophenolic acid AUC (mg*h/L; mean \pm SD) 47 ± 24 37 ± 11 0.06 Prednisone dose (mg per day; mean \pm SD) ^d 42 ± 18 39 ± 26 0.11 Month 1 13 ± 2 13 ± 3 0.60 Month 1 13 ± 2 13 ± 3 0.60 Month 1 13 ± 2 13 ± 3 0.60 Month 1 13 ± 2 13 ± 3 0.60 Month 1 13 ± 2 13 ± 3 0.60 Month 12 5 ± 1 5 ± 1 0.93 <	Cyclosporine trough level $(ng/mL; mean \pm SD)^d$			
Month 1 250 ± 94 249 ± 76 0.96 Month 3 198 ± 56 213 ± 52 0.45 Month 6 121 ± 47 145 ± 60 0.24 Month 12 117 ± 21 118 ± 49 0.87 Tacrolimus trough level (ng/mL; mean \pm SD) ^d 117 ± 21 118 ± 47 0.70 Week 1 10.6 ± 4.6 10.5 ± 6.6 0.99 Month 1 11.9 ± 6.3 11.8 ± 4.7 0.70 Month 3 9.1 ± 3.4 9.1 ± 3.6 1.0 Month 6 6.5 ± 2.0 6.5 ± 2.2 0.13 Month 12 6.3 ± 2.3 6.5 ± 2.1 0.64 Mycophenolate mofetil dose (g per day; mean \pm SD) ^d 1.92 ± 0.25 1.90 ± 0.22 0.63 Month 6 1.69 ± 0.45 1.73 ± 0.49 0.56 Month 1 1.69 ± 0.45 1.73 ± 0.49 0.56 Month 3 1.45 ± 0.49 1.53 ± 0.57 0.49 Month 6 1.34 ± 0.55 1.39 ± 0.58 0.49 Month 6 1.34 ± 0.55 1.39 ± 0.58 0.49 Month 12 1.25 ± 0.56 1.34 ± 0.58 0.51 Mycophenolic acid AUC (mg*h/L; mean \pm SD) 44 ± 18 39 ± 26 0.11 Month 3 47 ± 24 37 ± 11 0.06 Predinisone dose (mg per day; mean \pm SD) ^d 44 ± 18 39 ± 26 0.11 Month 3 10 ± 1 10 ± 2 0.85 Month 1 13 ± 2 13 ± 3 0.60 Month 1 13 ± 2 13 ± 3 0.60 Month 3 10 ± 1 1	Week 1	241 ± 53	233 ± 53	0.56
Month 3 Month 3198 ± 56 198 ± 56213 ± 52 213 ± 520.45 	Month 1	250 ± 94	249 ± 76	0.96
Month 6121 ± 47145 ± 600.24Month 12117 ± 21118 ± 490.87Tacrolimus trough level (ng/mL; mean ± SD) ^d 10.6 ± 4.6 10.5 ± 6.60.99Wenth 111.9 ± 6.311.8 ± 4.70.70Month 39.1 ± 3.49.1 ± 3.61.0Month 66.5 ± 2.06.5 ± 2.20.13Month 126.3 ± 2.36.5 ± 2.20.64Mycophenolate mofetil dose (g per day; mean ± SD) ^d 1.92 ± 0.25 1.90 ± 0.22 0.63Month 1 1.69 ± 0.45 1.73 ± 0.49 0.56Month 1 1.69 ± 0.45 1.73 ± 0.49 0.56Month 3 1.45 ± 0.49 1.53 ± 0.57 0.49Month 6 1.34 ± 0.55 1.39 ± 0.58 0.49Month 12 1.25 ± 0.56 1.34 ± 0.58 0.51Mycophenolic acid AUC (mg*h/L; mean ± SD) 44 ± 18 39 ± 26 0.11Month 3 47 ± 24 37 ± 11 0.06Prednisone dose (mg per day; mean ± SD) ^d 44 ± 18 39 ± 26 0.11Month 3 10 ± 1 10 ± 2 0.85Month 1 13 ± 2 13 ± 3 0.60Month 1 13 ± 2 13 ± 3 0.60Month 1 10 ± 1 10 ± 2 0.85Month 1 10 ± 1 10 ± 2 0.85Month 1 5 ± 1 5 ± 1 0.93	Month 3	198 ± 56	213 ± 52	0.45
Month 12117 ± 1118 ± 490.87Tacrolimus trough level (ng/mL; mean ± SD)d117 ± 21118 ± 490.87Week 110.6 ± 4.610.5 ± 6.60.99Month 111.9 ± 6.311.8 ± 4.70.70Month 39.1 ± 3.49.1 ± 3.61.0Month 66.5 ± 2.06.5 ± 2.20.13Month 126.3 ± 2.36.5 ± 2.10.64Mycophenolate mofetil dose (g per day; mean ± SD)d1.92 ± 0.251.90 ± 0.220.63Initial1.69 ± 0.451.73 ± 0.490.56Month 61.34 ± 0.551.39 ± 0.580.49Month 61.34 ± 0.551.39 ± 0.580.49Month 121.25 ± 0.561.34 ± 0.580.51Mycophenolic acid AUC (mg*h/L; mean ± SD) 44 ± 18 39 ± 260.11Month 347 ± 2437 ± 110.06Prednisone dose (mg per day; mean ± SD) ^d 20 ± 0 20 ± 3 0.75Month 113 ± 213 ± 30.60Month 310 ± 110 ± 20.85Month 45 ± 05 ± 10.75	Month 6	120 = 20 121 ± 47	145 ± 60	0.24
Tacrolimus trough level (ng/mL; mean \pm SD)d10.6 \pm 4.610.5 \pm 6.60.99Wonth 111.9 \pm 6.311.8 \pm 4.70.70Month 39.1 \pm 3.49.1 \pm 3.61.0Month 66.5 \pm 2.06.5 \pm 2.20.13Month 126.3 \pm 2.36.5 \pm 2.10.64Mycophenolate mofetil dose (g per day; mean \pm SD)d1.92 \pm 0.251.90 \pm 0.220.63Month 11.69 \pm 0.451.73 \pm 0.490.56Month 61.45 \pm 0.491.53 \pm 0.570.49Month 61.34 \pm 0.551.39 \pm 0.570.49Month 61.25 \pm 0.561.34 \pm 0.580.51Mycophenolic acid AUC (mg*h/L; mean \pm SD)44 \pm 1839 \pm 260.11Day 544 \pm 1839 \pm 260.11Month 30.20 \pm 020 \pm 30.75Month 113 \pm 213 \pm 30.60Month 310 \pm 110 \pm 20.85Month 113 \pm 213 \pm 30.60Month 11.92 \pm 0.540.92 \pm 0.85Month 11.92 \pm 0.540.93Month 11.92 \pm 0.54 \pm 00.93Month 11.93 \pm 20.55 \pm 1Month 10.91 \pm 0.92 \pm 0.85Month 11.92 \pm 0.94 \pm 0.93Month 10.92 \pm 0.93Month 10.92 \pm 0.93Month 10.92 \pm 0.93Month 10.92 \pm 0.93	Month 12	117 ± 21	118 ± 49	0.87
Week 110.6 ± 4.610.5 ± 6.60.99Month 111.9 ± 6.311.8 ± 4.70.70Month 39.1 ± 3.49.1 ± 3.61.0Month 66.5 ± 2.06.5 ± 2.20.13Month 126.3 ± 2.36.5 ± 2.10.64Mycophenolate mofetil dose (g per day; mean ± SD) ^d 1.92 ± 0.251.90 ± 0.220.63Initial1.69 ± 0.451.73 ± 0.490.56Month 11.69 ± 0.451.73 ± 0.490.56Month 31.45 ± 0.491.53 ± 0.570.49Month 61.34 ± 0.551.39 ± 0.580.49Month 121.25 ± 0.561.34 ± 0.580.51Mycophenolic acid AUC (mg*h/L; mean ± SD)44 ± 1839 ± 260.11Day 544 ± 1839 ± 260.11Month 320 ± 020 ± 30.75Month 113 ± 213 ± 30.60Month 310 ± 110 ± 20.85Month 113 ± 213 ± 30.60Month 11.5 ± 05 ± 10.75	Tacrolimus trough level $(ng/mL : mean + SD)^d$		110 - 17	0.07
Month 1 10.5 ± 10.5 10.5 ± 0.5 0.57 Month 3 9.1 ± 3.4 9.1 ± 3.6 1.0 Month 6 6.5 ± 2.0 6.5 ± 2.2 0.13 Month 12 6.3 ± 2.3 6.5 ± 2.1 0.64 Mycophenolate mofetil dose (g per day; mean \pm SD) ^d 1.92 ± 0.25 1.90 ± 0.22 0.63 Initial 1.69 ± 0.45 1.73 ± 0.49 0.56 Month 1 1.69 ± 0.45 1.73 ± 0.49 0.56 Month 3 1.45 ± 0.49 1.53 ± 0.57 0.49 Month 6 1.34 ± 0.55 1.39 ± 0.58 0.49 Month 12 1.25 ± 0.56 1.34 ± 0.58 0.51 Mycophenolic acid AUC (mg*h/L; mean \pm SD) 47 ± 24 37 ± 11 0.06 Prednisone dose (mg per day; mean \pm SD) ^d 47 ± 24 37 ± 11 0.06 Month 3 10 ± 1 10 ± 2 0.85 Month 1 13 ± 2 13 ± 3 0.60 Month 1 10 ± 1 10 ± 2 0.85 Month 1 5 ± 0 5 ± 1 0.75	Week 1	10.6 ± 4.6	10.5 ± 6.6	0.99
Month 3 113 ± 3.4 9.1 ± 3.6 1.0 Month 6 6.5 ± 2.0 6.5 ± 2.2 0.13 Month 12 6.3 ± 2.3 6.5 ± 2.1 0.64 Mycophenolate mofetil dose (g per day; mean \pm SD) ^d 1.92 ± 0.25 1.90 ± 0.22 0.63 Month 1 1.69 ± 0.45 1.73 ± 0.49 0.56 Month 3 1.45 ± 0.49 1.53 ± 0.57 0.49 Month 6 1.34 ± 0.55 1.39 ± 0.58 0.49 Month 12 1.25 ± 0.56 1.34 ± 0.58 0.51 Mycophenolic acid AUC (mg*h/L; mean \pm SD) 44 ± 18 39 ± 26 0.11 Day 5 44 ± 18 39 ± 26 0.11 Month 3 47 ± 24 37 ± 11 0.06 Prednisone dose (mg per day; mean \pm SD) ^d 20 ± 0 20 ± 3 0.75 Month 1 13 ± 2 13 ± 3 0.60 Month 1 10 ± 1 10 ± 2 0.85 Month 3 5 ± 0 5 ± 1 0.75	Month 1	11.9 ± 6.3	10.5 ± 0.0 11.8 ± 4.7	0.70
Month 6 (5 ± 2.1) (7 ± 5.1) (7 ± 5.1) (10 ± 5.1) Month 6 (5 ± 2.1) (6.5 ± 2.2) (1.3) Month 12 (5.3 ± 2.3) (5.5 ± 2.1) (0.64) Mycophenolate mofetil dose (g per day; mean \pm SD) ^d (1.92 ± 0.25) 1.90 ± 0.22 (0.63) Month 1 1.69 ± 0.45 1.73 ± 0.49 (0.56) Month 3 1.45 ± 0.49 1.53 ± 0.57 (0.49) Month 6 1.34 ± 0.55 1.39 ± 0.58 (0.49) Month 12 1.25 ± 0.56 1.34 ± 0.58 (0.51) Mycophenolic acid AUC (mg*h/L; mean \pm SD) (44 ± 18) 39 ± 26 (0.11) Day 5 (44 ± 18) 39 ± 26 (0.11) Month 3 (20 ± 0) 20 ± 3 (0.75) Month 1 13 ± 2 13 ± 3 (0.60) Month 1 (10 ± 1) (10 ± 2) (0.85) Month 1 (10 ± 1) (10 ± 2) (0.85) Month 12 (5 ± 1) (0.75) (0.75)	Month 3	91 + 34	91 + 36	1.0
Month 0 $0.5 = 2.6$ $0.5 = 2.2$ 0.64 Month 12 6.3 ± 2.3 6.5 ± 2.1 0.64 Mycophenolate mofetil dose (g per day; mean \pm SD) ^d 1 1.92 ± 0.25 1.90 ± 0.22 0.63 Month 1 1.69 ± 0.45 1.73 ± 0.49 0.56 Month 3 1.45 ± 0.49 1.53 ± 0.57 0.49 Month 6 1.34 ± 0.55 1.39 ± 0.58 0.49 Month 12 1.25 ± 0.56 1.34 ± 0.58 0.51 Mycophenolic acid AUC (mg*h/L; mean \pm SD) 44 ± 18 39 ± 26 0.11 Day 5 44 ± 18 39 ± 26 0.11 Month 3 47 ± 24 37 ± 11 0.06 Prednisone dose (mg per day; mean \pm SD) ^d 20 ± 0 20 ± 3 0.75 Month 1 13 ± 2 13 ± 3 0.60 Month 3 10 ± 1 10 ± 2 0.85 Month 4 5 ± 0 5 ± 1 0.75	Month 6	65 ± 20	65 ± 22	0.13
Mycophenolate mofetil dose (g per day; mean \pm SD) ^d 0.5 ± 2.5 0.6 ± 2.1 0.6 ± 2.1 Mycophenolate mofetil dose (g per day; mean \pm SD) ^d 1.92 ± 0.25 1.90 ± 0.22 0.63 Month 1 1.69 ± 0.45 1.73 ± 0.49 0.56 Month 3 1.45 ± 0.49 1.53 ± 0.57 0.49 Month 6 1.34 ± 0.55 1.39 ± 0.58 0.49 Month 12 1.25 ± 0.56 1.34 ± 0.58 0.51 Mycophenolic acid AUC (mg*h/L; mean \pm SD) 44 ± 18 39 ± 26 0.11 Day 5 44 ± 18 39 ± 26 0.11 Month 3 47 ± 24 37 ± 11 0.06 Prednisone dose (mg per day; mean \pm SD) ^d 20 ± 0 20 ± 3 0.75 Month 1 13 ± 2 13 ± 3 0.60 Month 3 10 ± 1 10 ± 2 0.85 Month 4 5 ± 0 5 ± 1 0.75	Month 12	6.3 ± 2.0 6.3 ± 2.3	6.5 ± 2.2	0.64
Initial 1.92 ± 0.25 1.90 ± 0.22 0.63 Month 1 1.69 ± 0.45 1.73 ± 0.49 0.56 Month 3 1.45 ± 0.49 1.53 ± 0.57 0.49 Month 6 1.34 ± 0.55 1.39 ± 0.58 0.49 Month 12 1.25 ± 0.56 1.34 ± 0.58 0.51 Mycophenolic acid AUC (mg*h/L; mean \pm SD) 44 ± 18 39 ± 26 0.11 Day 5 44 ± 18 39 ± 26 0.11 Month 3 47 ± 24 37 ± 11 0.06 Prednisone dose (mg per day; mean \pm SD) ^d 20 ± 0 20 ± 3 0.75 Month 1 13 ± 2 13 ± 3 0.60 Month 3 10 ± 1 10 ± 2 0.85 Month 4 5 ± 0 5 ± 1 0.75	Myconhenolate mofetil dose (α per day: mean + SD) ^d	0.5 = 2.5	0.0 = 2.1	0.01
Month 1 1.62 ± 0.42 1.73 ± 0.49 0.56 Month 3 1.45 ± 0.49 1.53 ± 0.57 0.49 Month 6 1.34 ± 0.55 1.39 ± 0.58 0.49 Month 12 1.25 ± 0.56 1.34 ± 0.58 0.51 Mycophenolic acid AUC (mg*h/L; mean \pm SD) 44 ± 18 39 ± 26 0.11 Day 5 44 ± 18 39 ± 26 0.11 Month 3 47 ± 24 37 ± 11 0.06 Prednisone dose (mg per day; mean \pm SD) ^d 20 ± 0 20 ± 3 0.75 Month 1 13 ± 2 13 ± 3 0.60 Month 3 10 ± 1 10 ± 2 0.85 Month 4 5 ± 0 5 ± 1 0.75	Initial	1.92 ± 0.25	1.90 ± 0.22	0.63
Month 1 1.05 ± 0.49 1.53 ± 0.57 0.49 Month 3 1.45 ± 0.49 1.53 ± 0.57 0.49 Month 6 1.34 ± 0.55 1.39 ± 0.58 0.49 Month 12 1.25 ± 0.56 1.34 ± 0.58 0.51 Mycophenolic acid AUC (mg*h/L; mean \pm SD) 44 ± 18 39 ± 26 0.11 Day 5 44 ± 18 39 ± 26 0.11 Month 3 47 ± 24 37 ± 11 0.06 Prednisone dose (mg per day; mean \pm SD) ^d 20 ± 0 20 ± 3 0.75 Month 1 13 ± 2 13 ± 3 0.60 Month 3 10 ± 1 10 ± 2 0.85 Month 4 5 ± 0 5 ± 1 0.75	Month 1	1.52 = 0.25 1.69 ± 0.45	1.70 ± 0.22 1.73 ± 0.49	0.55
Month 5 1.43 ± 0.57 1.39 ± 0.57 0.49 Month 6 1.34 ± 0.55 1.39 ± 0.58 0.49 Month 12 1.25 ± 0.56 1.34 ± 0.58 0.51 Mycophenolic acid AUC (mg*h/L; mean \pm SD) 44 ± 18 39 ± 26 0.11 Day 5 44 ± 18 39 ± 26 0.11 Month 3 47 ± 24 37 ± 11 0.06 Prednisone dose (mg per day; mean \pm SD) ^d 20 ± 0 20 ± 3 0.75 Month 1 13 ± 2 13 ± 3 0.60 Month 3 10 ± 1 10 ± 2 0.85 Month 6 5 ± 0 5 ± 1 0.75	Month 3	1.05 ± 0.13 1.45 ± 0.49	1.73 ± 0.19 1.53 ± 0.57	0.49
Month 0 1.54 ± 0.53 1.59 ± 0.50 0.45 Month 12 1.25 ± 0.56 1.34 ± 0.58 0.51 Mycophenolic acid AUC (mg*h/L; mean \pm SD) 1.25 ± 0.56 1.34 ± 0.58 0.51 Day 5 44 ± 18 39 ± 26 0.11 Month 3 47 ± 24 37 ± 11 0.06 Prednisone dose (mg per day; mean \pm SD) ^d 20 ± 0 20 ± 3 0.75 Month 1 13 ± 2 13 ± 3 0.60 Month 3 10 ± 1 10 ± 2 0.85 Month 6 5 ± 0 5 ± 1 0.75	Month 6	1.13 ± 0.15 1.34 ± 0.55	1.39 ± 0.57 1.39 ± 0.58	0.49
Mycophenolic acid AUC (mg*h/L; mean \pm SD) 1.25 \pm 0.30 1.34 \pm 0.30 0.31 Mycophenolic acid AUC (mg*h/L; mean \pm SD) 44 \pm 18 39 \pm 26 0.11 Day 5 44 \pm 18 39 \pm 26 0.11 Month 3 47 \pm 24 37 \pm 11 0.06 Prednisone dose (mg per day; mean \pm SD) ^d 20 \pm 0 20 \pm 3 0.75 Month 1 13 \pm 2 13 \pm 3 0.60 Month 3 10 \pm 1 10 \pm 2 0.85 Month 6 5 \pm 0 5 \pm 1 0.75 Month 12 5 \pm 1 0.93	Month 12	1.51 ± 0.55 1.25 ± 0.56	1.39 ± 0.58 1.34 ± 0.58	0.51
Imply the and ACC (hig h/L, hear \pm 3D) 44 ± 18 39 ± 26 0.11 Day 5 47 ± 24 37 ± 11 0.06 Prednisone dose (mg per day; mean \pm SD) ^d 20 ± 0 20 ± 3 0.75 Month 1 13 ± 2 13 ± 3 0.60 Month 3 10 ± 1 10 ± 2 0.85 Month 6 5 ± 0 5 ± 1 0.75	Mycophenolic acid AUC ($ma*h/I : mean + SD$)	1.25 ± 0.50	1.54 ± 0.50	0.01
$Day 3$ 44 ± 16 39 ± 20 0.11 Month 3 47 ± 24 37 ± 11 0.06 Prednisone dose (mg per day; mean \pm SD) ^d 20 ± 0 20 ± 3 0.75 Month 1 13 ± 2 13 ± 3 0.60 Month 3 10 ± 1 10 ± 2 0.85 Month 6 5 ± 0 5 ± 1 0.75	Day 5	14 ± 18	30 ± 26	0.11
Predniso dose (mg per day; mean \pm SD) ^d 47 ± 24 57 ± 11 0.00 Week 1 20 ± 0 20 ± 3 0.75 Month 1 13 ± 2 13 ± 3 0.60 Month 3 10 ± 1 10 ± 2 0.85 Month 6 5 ± 0 5 ± 1 0.75	Month 3	47 ± 10 47 ± 24	37 ± 20 37 ± 11	0.11
Week 1 20 ± 0 20 ± 3 0.75 Month 1 13 ± 2 13 ± 3 0.60 Month 3 10 ± 1 10 ± 2 0.85 Month 6 5 ± 0 5 ± 1 0.75	Prednisone dose (mg per day: mean $+$ SD) ^d	47 ± 24	J/ = 11	0.00
Week I 20 ± 0 20 ± 3 0.75 Month 1 13 ± 2 13 ± 3 0.60 Month 3 10 ± 1 10 ± 2 0.85 Month 6 5 ± 0 5 ± 1 0.75 Month 12 5 ± 1 0.93	Week 1	20 ± 0	20 ± 3	0.75
North 1 15 ± 2 15 ± 5 0.00 Month 3 10 ± 1 10 ± 2 0.85 Month 6 5 ± 0 5 ± 1 0.75 Month 12 5 ± 1 0.93	Month 1	20 ± 0 12 ± 2	20 ± 3 13 ± 3	0.75
Month 5 10 ± 1 10 ± 2 0.85 Month 6 5 ± 0 5 ± 1 0.75 Month 12 5 ± 1 0.93	Month 3	13 ± 2 10 ± 1	13 ± 3 10 ± 2	0.00
Month 12 5+1 0.73	Month 6	10 ± 1 5 + 0	10 ± 2 5 + 1	0.85
	Month 12	5 ± 0 5 + 1	5 ± 1 5 + 1	0.75

AUC, area under concentration curve.

Data are n (%) unless otherwise indicated.

^aAssessed in patients initially treated with cyclosporine. Reasons for switch in valganciclovir prophylaxis: 13 acute rejection episode (including borderline changes), 1 subclinical rejection, 1 gingival hyperplasia, 1 acute tubular necrosis; in valacyclovir prophylaxis: 16 acute rejection episode (including borderline changes), 2 gingival hyperplasia, 1 donor-related nephrosclerosis, 1 acute tubular necrosis, 1 cyclosporine nephrotoxicity, 1 acute pancreatitis.

^bAssessed in patients initially treated with tacrolimus. Reasons for switch in valganciclovir prophylaxis: 2 diarrhea, 2 polyomavirus-associated nephropathy; in valacyclovir prophylaxis: 1 diarrhea.

^cReasons for withdrawal in valganciclovir prophylaxis: 7 myelotoxicity, 4 gastrointestinal side effect, 2 severe bacterial infection, 1 acute pancreatitis; in valacyclovir prophylaxis: 7 gastrointestinal side effect, 5 myelotoxicity, 3 severe bacterial infection, 1 acute pancreatitis.

^dAssessed in patients with functioning graft.

^eIn 2 patients no calcineurin inhibitor was given.

Variables ^a	Hazard ratio	95% CI	P value
Biopsy-proven acute rejection			
Valacyclovir prophylaxis ^b	2.49	1.09 - 5.65	0.03
Basiliximab induction ^e	0.20	0.05 - 0.77	0.02
HLA mismatches (per 1 increase)	1.58	1.09 - 2.28	0.02
Polyoma BKV viremia			
Valacyclovir prophylaxis ^b	0.43	0.19 - 0.96	0.04
Tacrolimus ^d	2.27	1.09 - 4.73	0.03

Supplementary Table 2. Variables associated with biopsy-proven acute rejection and polyoma BKV viremia by multivariate Cox proportional hazard model

BKV, BK virus, CI, confidence interval

Data are n (%) unless otherwise indicated.

^aFollowing variables were included to analysis: age, previous transplantation, peak panel reactive antibodies, HLA mismatches, calcineurin inhibitor, type of induction therapy, donor age, donor type, expanded criteria donor, and delayed graft function.

^bValganciclovir prophylaxis is the reference group.

^cNo induction therapy is the reference group.

^dCyclosporine-based immunosuppression is the reference group.

Supplementary Table 3.	Characteristics	of patients	with CMV	disease

Patient/No. of	Study Group	D/R Status	Time to CMV	Peak CMV DNAemia	CMV Disease Type
Episodes	•		Disease (days)	(copies/mL)	• •
1/1	Valganciclovir	D+/R-	135	6550	Syndrome
2/1	Valganciclovir	D+/R+	135	2800	Syndrome
3/1	Valganciclovir	D+/R-	144	164500	Colitis
4/1	Valacyclovir	D+/R+	106	13350	Syndrome

CMV, cytomegalovirus; D, donor; R, recipient.

Supplementary Table 4. Patient and graft survival at 12 months and renal function parameters

Variables	Valganciclovir (n = 60)	Valacyclovir $(n = 59)$	P value
Patient survival ^a	60 (100)	56 (95)	0.08
Graft survival ^b	57 (95)	55 (93)	0.68
Delayed graft function	13 (22)	11 (19)	0.86
Serum creatinine (μ mol/L; mean \pm SD)			
Week 1	288 ± 220	292 ± 200	0.65
Month 1	156 ± 59	148 ± 57	0.17
Month 3	141 ± 36	134 ± 34	0.31
Month 12	136 ± 39	137 ± 44	0.92
$eGFR (mL/min; mean \pm SD)^{c}$			
Month 1	48 ± 16	48 ± 16	0.65
Month 3	58 ± 18	57 ± 19	0.57
Month 12	58 ± 23	60 ± 20	0.75

eGFR, estimated glomerular filtration rate.

Data are n (%) unless otherwise indicated.

^aReasons for death in valacyclovir prophylaxis: 1 hemorrhagic shock, 1 sepsis, 1 epileptic status.

^bReasons for graft loss in valganciclovir prophylaxis: 2 polyomavirus-associated nephropathy, 1 primary nonfunctioning graft; in valacyclovir prophylaxis: 3 death with functioning graft, 1 antibody-mediated rejection. ^cAccording to the MDRD7 formula.